GLAND — Gland Pharma Balance Sheet
0.000.00%
- IN₹232.82bn
- IN₹206.78bn
- IN₹56.65bn
- 93
- 22
- 18
- 40
Annual balance sheet for Gland Pharma, fiscal year end - March 31st, INR millions except per share, conversion factor applied.
2020 March 31st | 2021 March 31st | 2022 March 31st | 2023 March 31st | 2024 March 31st | |
---|---|---|---|---|---|
Period Length: | — | — | — | — | — |
Source: | PROSPECTUS | ARS | ARS | ARS | ARS |
Standards: | IAS | IAS | IAS | IAS | IAS |
Status: | Final | Final | Final | Final | Final |
Cash | |||||
Cash and Equivalents | |||||
Short Term Investments | |||||
Cash and Short Term Investments | 13,252 | 30,058 | 32,427 | 37,628 | 19,388 |
Net Total Accounts Receivable | |||||
Net Total Receivables | 7,311 | 8,188 | 13,599 | 11,381 | 18,908 |
Total Inventory | |||||
Prepaid Expenses | |||||
Total Other Current Assets | |||||
Total Current Assets | 28,463 | 51,236 | 58,521 | 69,008 | 56,452 |
Gross Property, Plant And Equipment | |||||
Accumulated Depreciation | |||||
Net Property, Plant And Equipment | 11,566 | 12,920 | 16,804 | 17,361 | 38,302 |
Net Goodwill | |||||
Net Intangible Assets | |||||
Long Term Investments | |||||
Long Term Notes Receivable | |||||
Other Long Term Assets | |||||
Total Assets | 40,860 | 64,961 | 78,336 | 87,775 | 106,612 |
Accounts Payable | |||||
Accrued Expenses | |||||
Notes Payable / Short Term Debt | |||||
Current Portion of Long Term Debt / Capital Leases | |||||
Total Other Current Liabilities | |||||
Total Current Liabilities | 3,590 | 5,125 | 5,820 | 7,291 | 13,984 |
Long Term Debt | |||||
Capital Lease Obligations | |||||
Total Long Term Debt | |||||
Total Debt | |||||
Deferred Income Tax | |||||
Total Other Liabilities | |||||
Total Funded Status | |||||
Total Liabilities | 4,398 | 5,928 | 6,760 | 8,188 | 19,374 |
Common Stock | |||||
Additional Paid In Capital | |||||
Retained Earnings (Accumulated Deficit) | |||||
Other Equity | |||||
Total Equity | 36,462 | 59,032 | 71,576 | 79,587 | 87,238 |
Total Liabilities & Shareholders' Equity | 40,860 | 64,961 | 78,336 | 87,775 | 106,612 |
Total Common Shares Outstanding |